The clinical impact of such monocyte/macrophage activation needs to be elucidated, but sCD163 has been shown as a risk factor for several non-AIDS-defining events, such as HIV-associated neurocognitive disorders, cardiovascular disease or liver fibrosis (22–24). This evidence concerns the gene CD163 and Hepatic fibrosis.